<img alt="" height="1" width="1" />Salix Pharmaceuticals Announces NDA Submission For XIFAXAN550 For Treatment of ...PipelineReview.com (press release)... (rifaximin) 550 mg tablets for the proposed indication of treatment of non-constipation irritable bowel syndrome (Non-C IBS) and IBS-related bloating. ...<nobr></nobr> |